about
Unilateral limited laminectomy as the approach of choice for the removal of thoracolumbar neurofibromas.Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.Solitary fibrous tumor of the liver.Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylationMulti-detector row computed tomography (MDCT) and magnetic resonance imaging (MRI) in the evaluation of the mandibular invasion by squamous cell carcinomas (SCC) of the oral cavity. Correlation with pathological dataActivity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerThe Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases.Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry studyRadionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.Weight of epilepsy in brain tumor patients.Correlation study between intravoxel incoherent motion MRI and dynamic contrast-enhanced MRI in head and neck squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes.Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients.Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy.Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report.Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.Assessment of diffusion parameters by intravoxel incoherent motion MRI in head and neck squamous cell carcinoma.Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.The prediction of the treatment response of cervical nodes using intravoxel incoherent motion diffusion-weighted imaging.Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study.Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.Early radiation-induced changes evaluated by intravoxel incoherent motion in the major salivary glands.Characterization of cervical lymph-nodes using a multi-parametric and multi-modal approach for an early prediction of tumor response to chemo-radiotherapy.Correlation study between DKI and conventional DWI in brain and head and neck tumors.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
P50
Q30949567-83460470-D985-4E99-A27E-A489FB53EDE9Q31158877-5BCDEF2C-C1C6-4C67-B111-75D0C333DDBFQ33273672-2CA24B3D-D41B-4BD0-AEB2-35527561EE32Q33368210-C1F02565-FA2F-4C6A-8920-C6649866BDF5Q33383951-ADF49DCE-D91F-41AF-BBC8-564E563C19D3Q33610806-77C39CBE-C116-4B89-A127-696A0ED0D4E5Q33625227-99A620B9-3ABC-4204-8072-F4DB8DEB52FFQ34452673-018D360D-4A89-4E7B-9431-8257E6115B16Q34552757-2D9E7FEB-482F-4997-AF9F-C0A123344281Q35992345-924A65AC-E8FC-4EEC-86D7-42F2B91352E0Q36641544-E57E8F5A-8199-44A1-8453-E7A36CC61202Q37141394-57AA586F-CCD6-4467-8F1F-DE27B6D43A2CQ37212272-3CC058B1-76A2-4035-9C1A-46C405FACCAFQ37747899-53CD94FF-C40A-45AA-930F-3929F63A2535Q38092731-BC5864D3-5F05-4BBF-91E9-898DD46FE7D9Q38721455-D38244D5-DB9E-4CDC-BF2C-8839FBAB195CQ39199891-E869B89C-BD6C-4227-8EA1-84B75D2106FBQ39290231-F8896481-CFDF-4D60-870F-AB3DD0DDA62DQ39887655-5DAC4BF9-C0A8-439F-8B7E-6218E9593BC6Q42651109-1BC19711-C321-428C-B8F1-72B77CDB9564Q42681369-17C305D9-B37A-4471-A7E0-0E366B6FA5CAQ42976471-CBE7DDBF-2CA2-43FB-A3E3-BD2C3DFCCB86Q43236058-8403DA5C-E474-4CE2-8D8B-771D6624CFD9Q43257040-13A7F21F-F6A9-4772-B3D7-858216329A6CQ43283104-71958F4D-007A-45BC-B1B0-0EC2A8B250E7Q43828519-24F1FE46-CF16-4721-8A3F-C1AC3D92E156Q44663938-9342A6FA-2853-44DA-931F-993032B4FD2DQ46414107-D3AB71E3-5B77-49B0-9948-15E367F13505Q46687391-00DD11F7-DCE3-4099-886A-79C50CE3C842Q46911563-96A30B58-13AB-4ABF-9A6B-D45612723A9CQ48495441-F8F80160-1089-4F42-9B39-7300947D4C47Q48610473-BF2A02A5-EB24-4691-AEBC-3BE60869D2BFQ50580695-C27C6830-2739-403B-8253-C075CC072652Q50692926-E8303658-F944-462D-9A53-8CBFC5C62E58Q51061507-6C453152-F29E-4F7D-B30A-371C517C16E8Q51097295-E77FEC96-C295-417C-B697-D4B8C5339FFDQ51805614-F78B85C3-C7B1-4ABA-BEBD-8DE6D56582B5Q52090958-80E29FEB-81C4-441D-A23C-2A42DF88CA0FQ52149377-ADCDC9B1-8125-4208-A2F0-B3BB322736D8Q52623784-F6F6808D-D42A-47AC-8A20-9788500F03AE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonello Vidiri
@ast
Antonello Vidiri
@en
Antonello Vidiri
@es
Antonello Vidiri
@nl
type
label
Antonello Vidiri
@ast
Antonello Vidiri
@en
Antonello Vidiri
@es
Antonello Vidiri
@nl
prefLabel
Antonello Vidiri
@ast
Antonello Vidiri
@en
Antonello Vidiri
@es
Antonello Vidiri
@nl
P1053
B-6641-2014
P106
P1153
6701524868
P21
P31
P3829
P496
0000-0001-6203-4642